PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
DOI:
https://doi.org/10.17140/POJ-3-e011Keywords:
Pancreatic cancer; Chemoresistance; DNA damage repair; Synthetic lethality; BRCA1/2; Germline mutations; Genomics;Abstract
Survival rates for pancreatic cancer remain dismal. Current standard of care treatment regimens provide transient clinical benefit but eventually chemoresistance develops. Tumors deficient in deoxyribonucleic acid (DNA) damage repair mechanisms such as BRCA mutants show better responses to platinum based agents, however, such tumors can utilize the poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) pathway as a salvage mechanism. Therefore, inhibition of PARP pathway could lead to tumor destruction and synthetic lethality in presence of BRCA mutation. Various PARP inhibitors have been approved for treatment of patients with germline or somatic BRCA mutant breast and ovarian cancer. This provides basis of using PARP inhibitors in patients with pancreatic cancer that harbor BRCA mutation. A recent phase III Pancreas Cancer Olaparib Ongoing (POLO) study showed impressive results with near doubling of progression free survival compared to placebo (7.4 vs 3.8 months). These results highlight the importance of germline testing for all patients with pancreatic cancer and inclusion of additional deficiencies in homologous recombination repair (ATM and PALB2) including BRCA variants of uncertain significance should be further explored.
References
American Cancer Society. Cancer Facts & Statistics. American Cancer Society. Web site. https://www.cancerstatisticscenter.can-cer.org/. Accessed July 9, 2019.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817-1825. doi: 10.1056/NEJMoa1011923
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29(34): 4548-4554. doi: 10.1200/JCO.2011.36.5742
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53(4): 549-554. doi: 10.1016/0092-8674(88)90571-5
Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene muta-tions in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994; 54(6): 1556- 1560.
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20(10): 1218-1249. doi: 10.1101/gad.1415606
Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008; 3: 157-188. doi: 10.1146/annurev.pathmechdis.3.121806.154305
Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol. 2011; 5(4): 387-393. doi: 10.1016/j.molonc.2011.07.001
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ri-bose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2): 123-134. doi: 10.1056/NEJMoa0900212
Roberts NJ, Norris AL, Petersen GM, et al. Whole genome Submit your article to this journal | https://openventio.org/submit-manuscript/ e8 Saif MW et al sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016; 6(2): 166-75. doi: 10.1158/2159-8290. CD-15-0402
Shindo K, Yu J, Suenaga M, et al. Deleterious germline mu-tations in patients with apparently sporadic pancreatic adeno-carcinoma. J Clin Oncol. 2017; 35(30): 3382-3390. doi: 10.1200/ JCO.2017.72.3502
Ferrone, C.R., Levine DA, Tang LH, et al. BRCA germline mu-tations in jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009. 27(3): 433-438. doi: 10.1200/JCO.2008.18.5546
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Ola-parib monotherapy in patients with advanced cancer and a ger-mline BRCA1/2 mutation. J Clin Oncol. 2015; 33(3): 244-250. doi: 10.1200/JCO.2014.56.2728
Shroff RT, Hendifar A, McWilliams RR, et al. Rucaparib mo-notherapy in patients with pancreatic cancer and a known delete-rious BRCA mutation. JCO Precis Oncol. 2018; 2018. doi: 10.1200/ PO.17.00316
Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib. Paper presented at: SGO An-nual Meeting; 2018; New Orleans, LA, USA.
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019; 381(4): 317-327. doi: 10.1056/NEJMoa1903387
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018; 379(26): 2495-2505. doi: 10.1056/NEJMoa1810858
Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homolo-gous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018; 2018. doi: 10.1200/PO.17.00286
Mateo J, Porta N, McGovern UB, et al. TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) in-hibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. J Clin On-col. 2019; 37(15_suppl): 5005-5005. doi: 10.1200/JCO.2019.37.15_ suppl.5005 Editorial | Volume 3 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
